@article{MuellerBroeckerKlinkeretal.2012,
  author    = {M{\"u}ller, P.A. and Br{\"o}cker, E.B. and Klinker, E. and Stoevesandt, J. and Benoit, S.},
  title     = {Adjuvant treatment of recalcitrant Bullous pemphigoid with immunoadsorption},
  series = {Dermatology},
  volume    = {224},
  journal   = {Dermatology},
  number    = {3},
  issn      = {1018-8665},
  doi       = {10.1159/000339071},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-196620},
  pages     = {224 -- 227},
  year      = {2012},
  abstract  = {Elimination of pathogenic autoantibodies by immunoadsorption (IA) has been described as an effective adjuvant treatment in severe bullous autoimmune diseases, especially in pemphigus. There is much less experience in the treatment of bullous pemphigoid (BP). BP was diagnosed in a 62-year-old Caucasian woman presenting a pruritic rash with multiple tense blisters. Standard treatments with topical and oral corticosteroids, steroid-sparing agents including dapsone, azathioprine, mycophenolate mofetil (MMF) and intravenous immunoglobulins were ineffective or had to be discontinued due to adverse events. An immediate clinical response could be achieved by two treatment cycles of adjuvant protein A immunoadsorption (PA-IA) in addition to continued treatment with MMF (2 g/day) and prednisolone (1 mg/kg/day). Tolerance was excellent. Clinical improvement remained stable after discontinuation of IA and went along with sustained reduction of circulating autoantibodies. Our data demonstrate that PA-IA might be a safe and effective adjuvant treatment in severe and recalcitrant BP.},
  language  = {en}
}
@phdthesis{Trulley2019,
  author    = {Trulley, Valerie-Noelle},
  title     = {Einfluss des NO-Donors DEA/NO auf die Integrit{\"a}t der inhibitorischen Signalwege und der Expression purinerger Rezeptoren bei der \(ex\) \(vivo\)-Lagerung von Thrombozyten},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-175096},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2019},
  abstract  = {Im Rahmen der Pr{\"a}paration und Lagerung von TKs entstehen bei Thrombozyten morphologische, funktionelle und h{\"a}mostatische Defizite, die unter dem Begriff storage lesion zusammengefasst werden. In dieser Dissertation wurde untersucht, ob durch Zugabe des kurzzeitig und reversibel wirksamen NO-Donors DEA/NO zu Apherese-TKs Zeichen der storage lesion {\"u}ber eine 5-t{\"a}gige Lagerung vermindert werden k{\"o}nnen. Daf{\"u}r wurde den Apherese-TKs direkt nach der Herstellung 5 nM DEA/NO zugesetzt. An den Tagen 0 (nach Abklingen der NO-Donor-Wirkung), 2 und 5 wurden verschiedene funktionelle Systeme der Thrombozyten analysiert. Verglichen mit fr{\"u}heren Untersuchungen von unbehandelten TKs ergab sich unter Einsatz von DEA/NO eine abgeschw{\"a}chte Aktivierung der inhibitorischen Signalwege mit geringerem Anstieg der VASP-Phosphorylierung und des cGMP-Spiegels sowie mit stabilem PDE5A-Gehalt. Gemessen anhand der P-Selektin-Expression und der Fibrinogenbindung zeigte sich ein unver{\"a}ndert niedriger Pr{\"a}aktivierungsgrad der Thrombozyten bei erhaltener Stimulierbarkeit. Bei der Oberfl{\"a}chenexpression von purinergen Rezeptoren war der R{\"u}ckgang der stimulierten Mobilisation w{\"a}hrend der 5-t{\"a}gigen Lagerung im Vergleich zu unbehandelten TKs vermindert. Damit war unter dem Einfluss von DEA/NO eine Abschw{\"a}chung von Ph{\"a}nomenen der storage lesion zu beobachten. F{\"u}r eine m{\"o}gliche klinische Anwendung des NO-Donors DEA/NO bei der TK-Herstellung sind allerdings weitere Studien bez{\"u}glich Wirksamkeit und m{\"o}glicher unerw{\"u}nschter Wirkungen in vivo notwendig. Dar{\"u}ber hinaus muss eine technische L{\"o}sung f{\"u}r die sterile Zugabe von DEA/NO gefunden werden.},
  subject      = {Thrombozytenkonzentrat},
  language  = {de}
}
@article{KoesslerHermannWeberetal.2016,
  author    = {Koessler, Juergen and Hermann, Stephanie and Weber, Katja and Koessler, Angela and Kuhn, Sabine and Boeck, Markus and Kobsar, Anna},
  title     = {Role of Purinergic Receptor Expression and Function for Reduced Responsiveness to Adenosine Diphosphate in Washed Human Platelets},
  series = {PLoS One},
  volume    = {11},
  journal   = {PLoS One},
  number    = {1},
  doi       = {10.1371/journal.pone.0147370},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-146400},
  pages     = {e0147370},
  year      = {2016},
  abstract  = {Background Washing of platelets is an important procedure commonly used for experimental studies, e.g. in cardiovascular research. As a known phenomenon, responsiveness to adenosine diphosphate (ADP) is reduced in washed platelets, although underlying molecular mechanisms—potentially interfering with experimental results—have not been thoroughly studied. Objectives Since ADP mediates its effects via three purinergic receptors P2Y1, P2X1 and P2Y12, their surface expression and function were investigated in washed platelets and, for comparison, in platelet-rich-plasma (PRP) at different time points for up to 2 hours after preparation. Results In contrast to PRP, flow cytometric analysis of surface expression in washed platelets revealed an increase of all receptors during the first 60 minutes after preparation followed by a significant reduction, which points to an initial preactivation of platelets and consecutive degeneration. The activity of the P2X1 receptor (measured by selectively induced calcium flux) was substantially maintained in both PRP and washed platelets. P2Y12 function (determined by flow cytometry as platelet reactivity index) was partially reduced after platelet washing compared to PRP, but remained stable in course of ongoing storage. However, the function of the P2Y1 receptor (measured by selectively induced calcium flux) continuously declined after preparation of washed platelets. Conclusion In conclusion, decreasing ADP responsiveness in washed platelets is particularly caused by impaired activity of the P2Y1 receptor associated with disturbed calcium regulation, which has to be considered in the design of experimental studies addressing ADP mediated platelet function.},
  language  = {en}
}
@article{BeckerAndersenHofmeisterMuelleretal.2012,
  author    = {Becker, J{\"u}rgen C. and Andersen, Mads H. and Hofmeister-M{\"u}ller, Valeska and Wobser, Marion and Frey, Lidia and Sandig, Christiane and Walter, Steffen and Singh-Jasuja, Harpreet and K{\"a}mpgen, Eckhart and Opitz, Andreas and Zapatka, Marc and Br{\"o}cker, Eva-B. and thor Straten, Per and Schrama, David and Ugurel, Selma},
  title     = {Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma},
  series = {Cancer Immunology, Immunotherapy},
  volume    = {61},
  journal   = {Cancer Immunology, Immunotherapy},
  number    = {11},
  doi       = {10.1007/s00262-012-1266-9},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-124830},
  pages     = {2091-2103},
  year      = {2012},
  abstract  = {Background Therapeutic vaccination directed to induce an anti-tumoral T-cell response is a field of extensive investigation in the treatment of melanoma. However, many vaccination trials in melanoma failed to demonstrate a correlation between the vaccine-specific immune response and therapy outcome. This has been mainly attributed to immune escape by antigen loss, rendering us in the need of new vaccination targets. Patients and methods This phase-II trial investigated a peptide vaccination against survivin, an oncogenic inhibitor-of-apoptosis protein crucial for the survival of tumor cells, in HLA-A1/-A2/-B35-positive patients with treatment-refractory stage-IV metastatic melanoma. The study endpoints were survivin-specific T-cell reactivity (SSTR), safety, response, and survival (OS). Results Sixty-one patients (ITT) received vaccination therapy using three different regimens. 55 patients (PP) were evaluable for response and survival, and 41/55 for SSTR. Patients achieving progression arrest (CR + PR + SD) more often showed SSTRs than patients with disease progression (p = 0.0008). Patients presenting SSTRs revealed a prolonged OS (median 19.6 vs. 8.6 months; p = 0.0077); multivariate analysis demonstrated SSTR as an independent predictor of survival (p = 0.013). The induction of SSTRs was associated with gender (female vs. male; p = 0.014) and disease stage (M1a/b vs. M1c; p = 0.010), but not with patient age, HLA type, performance status, or vaccination regimen. Conclusion Survivin-specific T-cell reactivities strongly correlate with tumor response and patient survival, indicating that vaccination with survivin-derived peptides is a promising treatment strategy in melanoma.},
  language  = {en}
}
@article{LeichtWeinigMayeretal.2018,
  author    = {Leicht, Hans Benno and Weinig, Elke and Mayer, Beate and Viebahn, Johannes and Geier, Andreas and Rau, Monika},
  title     = {Ceftriaxone-induced hemolytic anemia with severe renal failure: a case report and review of literature},
  series = {BMC Pharmacology and Toxicology},
  volume    = {19},
  journal   = {BMC Pharmacology and Toxicology},
  number    = {67},
  doi       = {10.1186/s40360-018-0257-7},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-176637},
  year      = {2018},
  abstract  = {Background: Drug induced immune hemolytic anemia (DIIHA) is a rare complication and often underdiagnosed. DIIHA is frequently associated with a bad outcome, including organ failure and even death. For the last decades, ceftriaxone has been one of the most common drugs causing DIIHA, and ceftriaxone-induced immune hemolytic anemia (IHA) has especially been reported to cause severe complications and fatal outcomes. Case Presentation: A 76-year-old male patient was treated with ceftriaxone for cholangitis. Short time after antibiotic exposure the patient was referred to intensive care unit due to cardiopulmonary instability. Hemolysis was observed on laboratory testing and the patient developed severe renal failure with a need for hemodialysis for 2 weeks. Medical history revealed that the patient had been previously exposed to ceftriaxone less than 3 weeks before with subsequent hemolytic reaction. Further causes for hemolytic anemia were excluded and drug-induced immune hemolytic (DIIHA) anemia to ceftriaxone could be confirmed. Conclusions: The case demonstrates the severity of ceftriaxone-induced immune hemolytic anemia, a rare, but immediately life-threatening condition of a frequently used antibiotic in clinical practice. Early and correct diagnosis of DIIHA is crucial, as immediate withdrawal of the causative drug is essential for the patient prognosis. Thus, awareness for this complication must be raised among treating physicians.},
  language  = {en}
}
@phdthesis{Schossee2023,
  author    = {Schossee, Nadine},
  title     = {Einfluss der Immunadsorption mit einer rekombinanten Protein A-basierten Adsorbers{\"a}ule auf die Zusammensetzung des peripheren Blutes},
  doi       = {10.25972/OPUS-31707},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-317075},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2023},
  abstract  = {In dieser Arbeit wurden die Effektivit{\"a}t und m{\"o}gliche Einfl{\"u}sse der Immunadsorption mit der auf rekombinantem Protein A-basierten Einmals{\"a}ule Ligasorb® auf bestimmte Blutparameter bei einer Kohorte von neurologischen Patienten mit Myasthenia gravis oder Stiff-Person-Syndrom evaluiert. Die IA mit der Ligasorb®-S{\"a}ule senkte effizient die Immunglobulinkonzentrationen IgG1, IgG2 und IgG4 im Patientenblut. Die durchschnittliche Reduktion dieser Plasmaproteine betrug 60\%. Die Reduktionsrate der Acetylcholinrezeptor-Autoantik{\"o}rper der MG Patienten lag bei 70\% nach IA. Die Blutkonzentrationen der Serumproteine wie Albumin oder der Komplementfaktoren C3 und C4 wurden durch die IA nicht wesentlich beeinflusst. Die IA zeigten auch keine klinisch relevanten Auswirkungen auf die zellul{\"a}re Blutzusammensetzung, insbesondere wurden keine Leukozytosen beobachtet. Die IA hatten außerdem keinen relevanten Einfluss auf die untersuchten klinisch-chemischen Parameter. Nach den IA konnte aber eine relevante St{\"o}rung der H{\"a}mostaseparameter festgestellt werden. Die Globaltests Quick, INR und PTT zeigten nach Behandlung deutlich pathologische Werte. Die nachfolgende Einzelfaktorbestimmung ergab Verminderungen der Vitamin K-abh{\"a}ngigen Gerinnungsfaktoren II, VII, IX und X um 42\% bis 67\%, die z.B. auf einer direkten Interaktion dieser Faktoren mit der Adsorbermatrix und/oder dem Liganden aus rekombinanten Protein A beruhen k{\"o}nnten. Nach 16 bis 20 Stunden zeigten sich die abweichenden Gerinnungsparameter wieder weitgehend normalisiert. Das Einhalten eines entsprechenden Zeitabstands bis zur Durchf{\"u}hrung anderer medizinischer Eingriffe, wie z.B. einer Lumbalpunktion, sowie eine vorherige Kontrolle der Globaltests TPZ und PTT sind daher anzuraten.},
  subject      = {Immunadsorption},
  language  = {de}
}
@phdthesis{Wiebecke2023,
  author    = {Wiebecke, Sophie Karolina},
  title     = {Einfluss mikrobieller Substanzen von Parodontitis-assoziierten Bakterien auf die Funktion humaner Thrombozyten},
  doi       = {10.25972/OPUS-32903},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-329038},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2023},
  abstract  = {Diese Arbeit untersuchte die Wirkung von bakteriellen Substanzen auf essenzielle thrombozyt{\"a}re Funktionen. Bei den Substanzen handelte es sich um Toxine von Bakterien, die mutmaßlich zur Pathogenese der Parodontitis beitragen. W{\"a}hrend LTX von Bakterium A. actinomycetemcomitans und C14 von F. nucleatum zur Hemmung der Aggregation und zur Stimulation inhibitorischer Systeme beitr{\"a}gt, induziert LPS von P. gingivalis eine leichte Aktivierung der Thrombozyten, gekennzeichnet durch eine gering verst{\"a}rkte P-Selektin-Expression.},
  subject      = {Parodontitis},
  language  = {de}
}
@phdthesis{Schuepferling2023,
  author    = {Sch{\"u}pferling, Anne Marie Heidi},
  title     = {Der Einfluss der Proteasomhemmung durch Bortezomib auf die Aktivierbarkeit humaner Thrombozyten},
  doi       = {10.25972/OPUS-32755},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-327551},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2023},
  abstract  = {Bortezomib, ein selektiver und potenter Proteasominhibitor, wird experimentell in der Tumorzellforschung sowie therapeutisch in der Therapie des Multiplen Myeloms eingesetzt. Die Wirkung auf die Thrombozytenfunktion war bislang unzureichend untersucht. Daher evaluiert diese Studie die dosisabh{\"a}ngige Wirkung von Bortezomib auf die Viabilit{\"a}t, die Aggregation von gewaschenen Thrombozyten und auf aktivierende Signalwege in gewaschenen Thrombozyten. Die Thrombozytenviabilit{\"a}t war bei hohen Bortezomibkonzentrationen von 100 - 200 µM vermindert. Passend dazu verminderten 100 - 200 µM Bortezomib die Phosphorylierung der ERK1/2 und der Akt/PKB in humanen Thrombozyten. Im Gegensatz dazu hatten diese hohen Bortezomibkonzentrationen keinen Einfluss auf das Niveau der p38 MAP Kinase-Phosphorylierung in aktivierten Thrombozyten. Die Thrombozytenaggregation, induziert durch hohe Konzentrationen von Kollagen oder TRAP-6, blieb unter 0,1 nM - 200 µM Bortezomib unver{\"a}ndert. Zusammenfassend l{\"a}sst sich sagen, dass Bortezomib weder die essenziellen, aktivierenden Signalwege noch die Initialisierung der Aggregation relevant beeinflusst. Das zeigt, dass diese Prozesse in Thrombozyten nicht abh{\"a}ngig von der Proteasomaktivit{\"a}t sind. Supramaximale Inhibierung des Proteasomsystems mit Bortezomibkonzentrationen von 100 µM oder mehr f{\"u}hren m{\"o}glicherweise zu ver{\"a}nderter Thrombozytenreaktionsf{\"a}higkeit, welche unter Umst{\"a}nden durch unspezifische und potenziell toxische Effekte mit erniedrigter Zellviabilit{\"a}t verursacht werden.},
  subject      = {Thrombozyt},
  language  = {de}
}
@phdthesis{Klingler2023,
  author    = {Klingler, Philipp},
  title     = {Exploration of proteasome interactions with human platelet function},
  doi       = {10.25972/OPUS-32108},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-321089},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2023},
  abstract  = {Platelets are anucleated cell fragments derived from megakaryocytes. They play a fundamental role in hemostasis, but there is rising evidence that they are also involved in immunological processes. Despite absence of a nucleus, human platelets are capable of de novo protein synthesis and contain a fully functional proteasome system, which is, in nucleated cells, involved in processes like cell cycle progression or apoptosis by its ability of protein degradation. The physiological significance of the proteasome system in human platelets is not yet fully understood and subject of ongoing research. Therefore, this study was conducted with the intention to outline the role of the proteasome system for functional characteristics of human platelets. For experimentation, citrated whole blood from healthy donors was obtained and preincubated with proteasome inhibitors. In addition to the commonly used bortezomib, the potent and selective proteasome inhibitor carfilzomib was selected as a second inhibitor to rule out agent-specific effects and to confirm that observed changes are related to proteasome inhibition. Irreversibly induced platelet activation and aggregation were not affected by proteasome blockade with bortezomib up to 24 hours. Conversely, proteasome inhibition led to enhanced threshold aggregation and agglutination up to 25 \%, accompanied by partial alleviation of induced VASP phosphorylation of approximately 10-15 \%. Expression of different receptors were almost unaffected. Instead, a significant increase of PP2A activity was observable in platelets after proteasome blockade, accompanied by facilitated platelet adhesion to coated surfaces in static experiments or flow chamber experiments. Carfilzomib, used for the first time in functional experimentation with human platelets in vitro, led to a dose-dependent decrease of proteasome activity with accumulation of poly ubiquitylated proteins. Like bortezomib, carfilzomib treatment resulted in enhanced threshold aggregation with attenuated VASP phosphorylation. As the main conclusion of this thesis, proteasome inhibition enhances the responsiveness of human platelets, provided by an alleviation of platelet inhibitory pathways and by an additional increase of PP2A activity, resulting in facilitated platelet adhesion under static and flow conditions. The proteasome system appears to be involved in the promotion of inhibitory counterregulation in platelets. The potential of proteasome inhibitors for triggering thromboembolic adverse events in patients must be clarified in further studies, in addition to their possible use for targeting platelet function to improve the hemostatic reactivity of platelets.},
  subject      = {Thrombozyt},
  language  = {en}
}
@article{KoesslerSchwarzWeberetal.2017,
  author    = {Koessler, Juergen and Schwarz, Michaela and Weber, Katja and Etzel, Julia and Koessler, Angela and Boeck, Markus and Kobsar, Anna},
  title     = {The role of adenosine diphosphate mediated platelet responsiveness for the stability of platelet integrity in citrated whole blood under ex vivo conditions},
  series = {PLoS ONE},
  volume    = {12},
  journal   = {PLoS ONE},
  number    = {11},
  doi       = {10.1371/journal.pone.0188193},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-159879},
  pages     = {e0188193},
  year      = {2017},
  abstract  = {Background: Platelets are important for effective hemostasis and considered to be involved in pathophysiological processes, e.g. in cardiovascular diseases. Platelets provided for research or for therapeutic use are frequently separated from citrated whole blood (WB) stored for different periods of time. Although functionally intact platelets are required, the stability of platelet integrity, e.g. adenosine diphosphate (ADP) mediated responsiveness, has never been thoroughly investigated in citrated WB under ex vivo conditions. Objectives: Platelet integrity was evaluated at different time points in citrated WB units, collected from healthy donors and stored for 5 days at ambient temperature. The analysis included the measurement of activation markers, of induced light transmission aggregometry and of purinergic receptor expression or function. Inhibitory pathways were explored by determination of basal vasodilator-stimulated phosphoprotein (VASP)-phosphorylation, intracellular cyclic nucleotide levels and the content of phosphodiesterase 5A. Fresh peripheral blood (PB) samples served as controls. Results: On day 5 of storage, thrombin receptor activating peptide-6 (TRAP-6) stimulated CD62P expression and fibrinogen binding were comparable to PB samples. ADP induced aggregation continuously decreased during storage. Purinergic receptor expression remained unchanged, whereas the P2Y1 activity progressively declined in contrast to preserved P2Y12 and P2X1 function. Inhibitory pathways were unaffected except for a slight elevation of VASP phosphorylation at Ser\(^{239}\) on day 5. Conclusion: After 5 days of storage in citrated WB, platelet responsiveness to TRAP-6 is sufficiently maintained. However, ADP-mediated platelet integrity is more sensitive to deterioration, especially after storage for more than 2 days. Decreasing ADP-induced aggregation is particularly caused by the impairment of the purinergic receptor P2Y1 activity. These characteristics should be considered in the use of platelets from stored citrated WB for experimental or therapeutic issues.},
  language  = {en}
}